GlaxoSmithKline Consumer Nigeria Past Earnings Performance
Past criteria checks 2/6
GlaxoSmithKline Consumer Nigeria's earnings have been declining at an average annual rate of -1.9%, while the Pharmaceuticals industry saw earnings growing at 8.7% annually. Revenues have been growing at an average rate of 3.1% per year. GlaxoSmithKline Consumer Nigeria's return on equity is 7.9%, and it has net margins of 4.6%.
Key information
-1.9%
Earnings growth rate
-1.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 21.6% |
| Revenue growth rate | 3.1% |
| Return on equity | 7.9% |
| Net Margin | 4.6% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How GlaxoSmithKline Consumer Nigeria makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 15,849 | 736 | 6,609 | 0 |
| 30 Jun 23 | 18,322 | 762 | 5,324 | 0 |
| 31 Mar 23 | 22,041 | 732 | 5,685 | 0 |
| 31 Dec 22 | 25,382 | 771 | 6,001 | 0 |
| 30 Sep 22 | 26,423 | 1,020 | 5,529 | 0 |
| 30 Jun 22 | 27,399 | 948 | 5,961 | 0 |
| 31 Mar 22 | 26,348 | 1,091 | 5,756 | 0 |
| 31 Dec 21 | 22,450 | 659 | 5,367 | 0 |
| 30 Sep 21 | 21,301 | 311 | 5,521 | 0 |
| 30 Jun 21 | 20,726 | 290 | 5,292 | 0 |
| 31 Mar 21 | 19,767 | 264 | 5,021 | 0 |
| 31 Dec 20 | 21,295 | 622 | 5,114 | 0 |
| 30 Sep 20 | 21,292 | 924 | 5,397 | 0 |
| 30 Jun 20 | 21,227 | 937 | 5,222 | 0 |
| 31 Mar 20 | 20,736 | 935 | 5,382 | 0 |
| 31 Dec 19 | 20,760 | 917 | 5,262 | 0 |
| 30 Sep 19 | 20,353 | 693 | 5,483 | 0 |
| 30 Jun 19 | 19,782 | 628 | 5,354 | 0 |
| 31 Mar 19 | 19,211 | 462 | 5,343 | 0 |
| 31 Dec 18 | 18,411 | 618 | 5,343 | 0 |
| 30 Sep 18 | 18,578 | 1,490 | 4,391 | 0 |
| 30 Jun 18 | 17,229 | 827 | 4,519 | 0 |
| 31 Mar 18 | 16,454 | 753 | 4,494 | 0 |
| 31 Dec 17 | 16,090 | 486 | 4,517 | 0 |
| 30 Sep 17 | 15,061 | 9,447 | 3,857 | 0 |
| 30 Jun 17 | 14,997 | 3,612 | 4,004 | 0 |
| 31 Mar 17 | 14,082 | 2,254 | 3,495 | 0 |
| 31 Dec 16 | 14,385 | 2,378 | 3,437 | 0 |
| 30 Sep 16 | 3,160 | -7,334 | 955 | 0 |
| 30 Jun 16 | 6,789 | -636 | 1,674 | 0 |
| 31 Mar 16 | 12,088 | 692 | 2,961 | 0 |
| 31 Dec 15 | 15,392 | 873 | 3,950 | 0 |
| 30 Sep 15 | 30,349 | 853 | 8,225 | 0 |
| 30 Jun 15 | 30,297 | 1,283 | 7,965 | 0 |
| 31 Mar 15 | 30,174 | 1,530 | 8,017 | 0 |
| 31 Dec 14 | 30,521 | 1,849 | 7,818 | 0 |
| 30 Sep 14 | 31,063 | 2,469 | 7,647 | 0 |
| 30 Jun 14 | 30,854 | 2,356 | 7,905 | 0 |
| 31 Mar 14 | 30,060 | 2,938 | 7,598 | 0 |
| 31 Dec 13 | 29,184 | 2,919 | 7,425 | 0 |
| 30 Sep 13 | 27,887 | 2,869 | 12,054 | 0 |
| 30 Jun 13 | 26,461 | 2,937 | 9,888 | 0 |
| 31 Mar 13 | 25,848 | 2,881 | 8,151 | 0 |
Quality Earnings: GLAXOSMITH has high quality earnings.
Growing Profit Margin: GLAXOSMITH's current net profit margins (4.6%) are higher than last year (3.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GLAXOSMITH's earnings have declined by 1.9% per year over the past 5 years.
Accelerating Growth: GLAXOSMITH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GLAXOSMITH had negative earnings growth (-27.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-11%).
Return on Equity
High ROE: GLAXOSMITH's Return on Equity (7.9%) is considered low.